文献速递艾滋病与性传播感染结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

使用电子剂量监测测量的依从性与HIV/AIDS及耐多药结核病患者中新发抗逆转录病毒耐药和不良结局相关

Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2022-01-01

在南非KwaZulu-Natal一家公立医院开展的前瞻性队列(PRAXIS研究)纳入198例接受抗逆转录病毒治疗(ART)并启动含贝达喹啉耐多药结核(MDR-TB)治疗的MDR-TB/HIV成人,用电子剂量监测(EDM)累计计算6个月依从性。11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药;ART依从性与ART耐药和死亡独立相关,模型显示依从性与新发耐药呈显著线性关联(P < .001),未发现特定阈值。

要点

  • EDM测量的ART依从性与新发ART耐药及死亡独立相关。
  • 11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药。
  • 依从性与新发耐药呈显著线性关联(P < .001),无特定阈值。

核心结论

  • 研究结果强调需要ART耐药检测,尤其在MDR-TB/HIV患者中,而资源有限地区目前未将其作为标准诊疗。
  • 尽管随访时间短,ART依从性降低与新发耐药和死亡率增加显著相关。

研究设计与样本

  • 前瞻性队列(PRAXIS研究),在南非KwaZulu-Natal一家公立医院纳入198例接受ART并启动含贝达喹啉MDR-TB治疗的MDR-TB/HIV成人。
  • 参与者使用独立EDM设备测量对贝达喹啉和ART(奈韦拉平或洛匹那韦/利托那韦)的依从性,依从性按6个月累计计算。
  • 随访至MDR-TB治疗完成,中位随访17.2个月(四分位距12.2-19.6)。
  • 对HIV RNA ≥1000 copies/mL的样本在基线、2个月和6个月进行HIV基因组测序。

主要发现

  • 2016年11月至2018年2月共纳入并随访198例MDR-TB/HIV患者,中位随访17.2个月(四分位距12.2-19.6)。
  • 11%有基线ART耐药突变,7.5%在6个月出现新发ART耐药。
  • ART依从性与ART耐药和死亡独立相关。
  • 模型显示ART依从性与新发耐药呈显著线性关联(P < .001),提示强关联但无特定阈值。

临床怎么用

  • 作者认为研究结果强调需要ART耐药检测,尤其在MDR-TB/HIV患者中,而资源有限地区目前未将其作为标准诊疗。

局限性

  • 尽管随访时间短,ART依从性降低与新发耐药和死亡率增加显著相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medication adherence is known to challenge treatment of human immunodeficiency virus (HIV)/AIDS and multidrug-resistant tuberculosis (MDR-TB). We hypothesized that adherence using electronic dose monitoring (EDM) would identify an antiretroviral therapy (ART) adherence threshold for emergent ART resistance and predict treatment outcomes in patients with MDR-TB and HIV on ART and bedaquiline-containing TB regimens. METHODS: A prospective cohort of adults with MDR-TB and HIV on ART and initiating MDR-TB treatment with bedaquiline were enrolled at a public hospital in KwaZulu-Natal, South Africa (PRAXIS Study). Participants received separate EDM devices that measure adherence to bedaquiline and ART (nevirapine or lopinavir/ritonavir). Adherence was calculated cumulatively over 6 months. Participants were followed through completion of MDR-TB treatment. HIV genome sequencing was performed at baseline and 2 and 6 months on samples with HIV RNA ≥1000 copies/mL. RESULTS: From November 2016 through February 2018, 198 persons with MDR-TB and HIV were enrolled and followed (median, 17.2 months; interquartile range, 12.2-19.6). Eleven percent had baseline ART resistance mutations, and 7.5% developed emergent ART resistance at 6 months. ART adherence was independently associated with ART resistance and mortality. Modeling identified a significant (P < .001), linear association between ART adherence and emergent resistance, suggesting a strong association without a specific threshold. CONCLUSIONS: Our findings highlight the need for ART resistance testing, especially in patients with MDR-TB and HIV, which is currently not the standard of care in resource-limited settings. Despite short follow-up duration, reduced ART adherence was significantly associated with emergent resistance and increased mortality. CLINICAL TRIALS REGISTRATION: NCT03162107.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bateman M, Wolf A, Chimukangara B, et al. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2022. PMID: 35352097. doi:10.1093/cid/ciac232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。